Tim Surgenor co-founded Red Sky Partners in 2009 and is its managing partner. He is a creative biotechnology industry professional who has held executive leadership positions in companies focused on commercializing pioneering biotechnology products. He is skilled in public and private company corporate governance, strategy, finance, business development and all functional aspects of product development.
Since founding Red Sky, Tim has been a trusted advisor to biotechnology CEOs and board members, served in interim general management positions and led a wide range of consulting assignments. Recent assignments include leading the virtual management team for Merrimack Pharmaceuticals, leading the process which resulted in Kymera Therapeutics’ protein engineering deal with Sanofi, and numerous interim CBO roles with public and private companies. Tim has long term advisory relationships with a number of public and private biotech clients including several at late stage clinical and commercial stages of development.
Tim has more than 40 years of general management experience in biotechnology companies, with executive roles including public company CEO, CFO, public company board member and audit committee chair. Previously, Tim was Executive Vice President of Haemonetics, where he ran business development and global marketing and led numerous technology and company acquisitions. As President of Genzyme’s Tissue Repair Division, he led the worldwide launch of several cellular therapy products and was a member of the Genzyme Corporation’s investor relations and financing team. Tim has also served as CEO of Cyberkinetics, a publicly traded neurotechnology company and CFO of BioSurface Technology, a publicly traded cell therapy company.
Tim has an MBA from the Harvard Graduate School of Business Administration a BA in Biochemistry from Williams College.